Artivila Biopharma is a clinical-stage biotechnology company that focuses on empowering innovative drug discovery with an advanced AIDD+CADD drug discovery platform. With years of successful drug discovery experience and track record, we focus on Autoimmune Diseases and Neurodegenerative Diseases, plus opportunistically Cancers. Our strong innovative drug discovery capability has ensured a high value pipeline including a phase II ready asset. Company has raised $42 million to date, and A-round fund raising is underway.

Using Artivila eLead platform combined with in vitro and in vivo capabilities, we have developed a pipeline including a clinical-stage dual inhibitor ARD-885 targeting IRAK4/1 for autoimmune diseases (completed Phase 1 study with excellent PK/PD and safety profile. Phase 2 in preparation for RA & SLE), an IND-stage candidate ARD-489AD targeting neurodegenerative indications, immune-checkpoint biologics and small molecule inhibitors in cancer and inflammation.